Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody for the treatment of thyroid eye disease; VRDN-002, a biosuperior IGF-1R antibody; and VRDN-003, an IGF-1R antibody product specifically designed for thyroid eye disease. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021. Viridian Therapeutics, Inc. was founded in 2006 and is based in Boulder, Colorado.
IPO Year: 2014
Exchange: NASDAQ
Website: viridiantherapeutics.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/19/2024 | $37.00 → $27.00 | Overweight → Equal Weight | Wells Fargo |
| 11/25/2024 | Buy | TD Cowen | |
| 9/11/2024 | $30.00 → $38.00 | Buy | Needham |
| 6/11/2024 | $29.00 | Outperform | Wolfe Research |
| 6/6/2024 | $23.00 | Buy | Goldman |
| 5/9/2024 | Buy → Neutral | Ladenburg Thalmann | |
| 5/9/2024 | $25.00 → $20.00 | Buy → Neutral | B. Riley Securities |
| 6/14/2023 | $51.00 | Outperform | Credit Suisse |
| 6/14/2023 | $46.00 | Buy | BTIG Research |
| 5/30/2023 | $44.00 | Outperform | RBC Capital Mkts |
4 - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)
4 - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)
4 - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)
4 - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)